Английская Википедия:Aripiprazole/sertraline
Шаблон:Short description Шаблон:Drugbox
Aripiprazole/sertraline (developmental code name ASC-01) is a combination formulation of aripiprazole (Abilify), an atypical antipsychotic, and sertraline (Zoloft), a selective serotonin reuptake inhibitor (SSRI), which was under development by Otsuka Pharmaceutical for the treatment of major depressive disorder (MDD).[1] It combines serotonin reuptake inhibition from sertraline and modulation of dopamine and serotonin receptors from aripiprazole.[1][2] In July 2017, it was in preregistration in Japan for the treatment of MDD.[1] However, in September 2018, the regulatory submission in Japan for MDD was withdrawn.[3]
See also
References
Шаблон:Antidepressants
Шаблон:Dopamine receptor modulators
Шаблон:Monoamine reuptake and release modulators
Шаблон:Serotonin receptor modulators
Шаблон:Nervous-system-drug-stub